PMC:7321036 / 47153-47305 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T378","span":{"begin":31,"end":36},"obj":"Body_part"}],"attributes":[{"id":"A378","pred":"fma_id","subj":"T378","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"(J and K) Vero E6 or A549-ACE2 cells were treated with PIKFYVE inhibitor apilimod (J) or the CDK inhibitor dinaciclib (K) prior to SARS-CoV-2 infection."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T233","span":{"begin":131,"end":139},"obj":"Disease"},{"id":"T234","span":{"begin":142,"end":151},"obj":"Disease"}],"attributes":[{"id":"A233","pred":"mondo_id","subj":"T233","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A234","pred":"mondo_id","subj":"T234","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"(J and K) Vero E6 or A549-ACE2 cells were treated with PIKFYVE inhibitor apilimod (J) or the CDK inhibitor dinaciclib (K) prior to SARS-CoV-2 infection."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T590","span":{"begin":10,"end":14},"obj":"http://purl.obolibrary.org/obo/CLO_0009524"},{"id":"T591","span":{"begin":10,"end":14},"obj":"http://purl.obolibrary.org/obo/CLO_0050515"},{"id":"T592","span":{"begin":21,"end":25},"obj":"http://purl.obolibrary.org/obo/CLO_0001601"},{"id":"T593","span":{"begin":21,"end":25},"obj":"http://purl.obolibrary.org/obo/CLO_0050025"},{"id":"T594","span":{"begin":21,"end":25},"obj":"http://purl.obolibrary.org/obo/CLO_0054264"},{"id":"T595","span":{"begin":21,"end":25},"obj":"http://purl.obolibrary.org/obo/CLO_0054265"},{"id":"T596","span":{"begin":21,"end":25},"obj":"http://purl.obolibrary.org/obo/CLO_0054266"},{"id":"T597","span":{"begin":21,"end":25},"obj":"http://purl.obolibrary.org/obo/CLO_0054267"},{"id":"T598","span":{"begin":21,"end":25},"obj":"http://purl.obolibrary.org/obo/CLO_0054268"},{"id":"T599","span":{"begin":21,"end":25},"obj":"http://purl.obolibrary.org/obo/CLO_0054269"},{"id":"T600","span":{"begin":31,"end":36},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"(J and K) Vero E6 or A549-ACE2 cells were treated with PIKFYVE inhibitor apilimod (J) or the CDK inhibitor dinaciclib (K) prior to SARS-CoV-2 infection."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T331","span":{"begin":63,"end":72},"obj":"Chemical"},{"id":"T332","span":{"begin":93,"end":106},"obj":"Chemical"},{"id":"T333","span":{"begin":97,"end":106},"obj":"Chemical"}],"attributes":[{"id":"A331","pred":"chebi_id","subj":"T331","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A332","pred":"chebi_id","subj":"T332","obj":"http://purl.obolibrary.org/obo/CHEBI_82665"},{"id":"A333","pred":"chebi_id","subj":"T333","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"(J and K) Vero E6 or A549-ACE2 cells were treated with PIKFYVE inhibitor apilimod (J) or the CDK inhibitor dinaciclib (K) prior to SARS-CoV-2 infection."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T331","span":{"begin":93,"end":106},"obj":"http://purl.obolibrary.org/obo/GO_0004861"}],"text":"(J and K) Vero E6 or A549-ACE2 cells were treated with PIKFYVE inhibitor apilimod (J) or the CDK inhibitor dinaciclib (K) prior to SARS-CoV-2 infection."}

{"project":"LitCovid-PubTator","denotations":[{"id":"994","span":{"begin":107,"end":117},"obj":"Chemical"},{"id":"995","span":{"begin":131,"end":151},"obj":"Disease"},{"id":"996","span":{"begin":15,"end":17},"obj":"CellLine"},{"id":"997","span":{"begin":21,"end":30},"obj":"CellLine"}],"attributes":[{"id":"A994","pred":"tao:has_database_id","subj":"994","obj":"MESH:C553669"},{"id":"A995","pred":"tao:has_database_id","subj":"995","obj":"MESH:C000657245"},{"id":"A996","pred":"tao:has_database_id","subj":"996","obj":"CVCL:4582"},{"id":"A997","pred":"tao:has_database_id","subj":"997","obj":"CVCL:0023"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"(J and K) Vero E6 or A549-ACE2 cells were treated with PIKFYVE inhibitor apilimod (J) or the CDK inhibitor dinaciclib (K) prior to SARS-CoV-2 infection."}

{"project":"LitCovid-sentences","denotations":[{"id":"T315","span":{"begin":0,"end":152},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"(J and K) Vero E6 or A549-ACE2 cells were treated with PIKFYVE inhibitor apilimod (J) or the CDK inhibitor dinaciclib (K) prior to SARS-CoV-2 infection."}